<DOC>
	<DOC>NCT01060904</DOC>
	<brief_summary>The purpose of this study is to assess the safety profile of brentuximab vedotin in combination with multi-agent chemotherapy in treatment-naive Stage IIa or IIb-IV Hodgkin lymphoma. It is a phase 1, two-arm, open-label dose escalation study designed to define the maximum tolerated dose, pharmacokinetics, immunogenicity and anti-tumor activity of brentuximab vedotin in combination with frontline therapy.</brief_summary>
	<brief_title>A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Treatmentnaive Hodgkin lymphoma, Stage IIa or IIbIV Measurable disease of at least 1.5 cm Eastern Cooperative Oncology Group performance status &lt;3 History of another primary malignancy that has not been in remission for at least 3 years Known cerebral/meningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens, CD30</keyword>
	<keyword>Disease, Hodgkin</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>monomethyl auristatin E</keyword>
</DOC>